Dynavax Technologies (NASDAQ:DVAX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Dynavax Technologies (NASDAQ:DVAXGet Rating) released its earnings results on Thursday. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.02), MarketWatch Earnings reports. Dynavax Technologies had a return on equity of 115.98% and a net margin of 23.12%. During the same quarter in the previous year, the company posted $0.01 earnings per share.

DVAX stock traded up $0.18 during trading on Friday, hitting $8.94. 3,382,106 shares of the company’s stock traded hands, compared to its average volume of 1,417,119. The firm has a market capitalization of $1.13 billion, a P/E ratio of 16.25 and a beta of 1.44. Dynavax Technologies has a 1 year low of $7.09 and a 1 year high of $21.39. The company has a quick ratio of 1.64, a current ratio of 1.75 and a debt-to-equity ratio of 0.99. The business has a fifty day simple moving average of $10.48 and a two-hundred day simple moving average of $13.21.

In other Dynavax Technologies news, SVP Robert Janssen sold 24,036 shares of the stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $10.57, for a total value of $254,060.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO David F. Novack sold 41,862 shares of the company’s stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $10.57, for a total transaction of $442,481.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 170,496 shares of company stock valued at $1,801,527. 9.31% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in Dynavax Technologies by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 1,914,607 shares of the biopharmaceutical company’s stock valued at $26,938,000 after purchasing an additional 101,297 shares during the last quarter. Morgan Stanley grew its stake in Dynavax Technologies by 176.1% during the 2nd quarter. Morgan Stanley now owns 1,789,695 shares of the biopharmaceutical company’s stock valued at $17,629,000 after purchasing an additional 1,141,462 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Dynavax Technologies by 8.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 857,326 shares of the biopharmaceutical company’s stock valued at $12,063,000 after purchasing an additional 67,923 shares during the last quarter. Norges Bank purchased a new stake in Dynavax Technologies during the 4th quarter valued at about $10,553,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Dynavax Technologies by 26.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 403,151 shares of the biopharmaceutical company’s stock valued at $7,745,000 after buying an additional 84,849 shares during the period. Institutional investors and hedge funds own 76.80% of the company’s stock.

Several research firms have recently commented on DVAX. StockNews.com began coverage on shares of Dynavax Technologies in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 1st. HC Wainwright assumed coverage on shares of Dynavax Technologies in a research note on Wednesday, January 12th. They set a “buy” rating and a $28.00 price target on the stock. Finally, TheStreet raised shares of Dynavax Technologies from a “d+” rating to a “c” rating in a research note on Wednesday, March 30th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $21.00.

About Dynavax Technologies (Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Articles

Earnings History for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.